Inhaled levodopa for intermittent treatment of OFF episodes in patients with Parkinson’s disease

References

• Olanow CW, Stocchi F. Levodopa: A new look at an old friend. Mov Disord. 2018;33(6):859–866.
   PubMed Web of Science ®Google Scholar
• Kikuchi S. Motor fluctuations in Parkinson’s disease. J Neurol. 2007;254(Suppl 5):32–40.
   Web of Science ®Google Scholar
• Obeso JA, Rodrigues-Oroz M, MArin C, et al. The origin of motor fluctuations in Parkinson’s disease: importance of dopaminergic innervation and basal ganglia circuits. Neurology. 2004;62(1):S17–S30.
   PubMed Web of Science ®Google Scholar
• De La Fuente-Fernández R, Schulzer M, Mak E, et al. Presynaptic mechanisms of motor fluctuations in Parkinson’s disease: A probabilistic model. Brain. 2004;127(4):888–899.
   PubMedGoogle Scholar
• Linazasoro G, Antonini A, Maguire RP, et al. Pharmacological and PET studies in patient’s with Parkinson’s disease and a short duration-motor response: implications in the pathophysiology of motor complications. J Neural Transm. 2004;111(4):497–509.
   PubMed Web of Science ®Google Scholar
• Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16(3):448–458.
   PubMed Web of Science ®Google Scholar
• Quinn N. Classification of fluctuations in patients with Parkinson’s disease. Neurology. 1998;51(suppl2):S25–29.
   PubMedGoogle Scholar
• Adler CH. Relevance of motor complications in Parkinson’s disease. Neurology. 2002;58(4 Suppl 1):S51–6.
   PubMed Web of Science ®Google Scholar
• Lieberman A, Vijay M. Wearing-off of levodopa of greatest concern for PD patients. Eur J Neurol. 2004;11(S2):109.
   Web of Science ®Google Scholar
• Marrinan S, Emmanuel AV, Burn DJ. Delayed gastric emptying in Parkinson’s disease. Mov Disord. 2014;29(1):23–32.
   PubMed Web of Science ®Google Scholar
• Doi H, Sakakibara R, Sato M, et al. Plasma levodopa peak delay and impaired gastric emptying in Parkinson’s disease. J Neurol Sci. 2012;319(1–2):86–88.
   PubMed Web of Science ®Google Scholar
• Fox SH, Katzenschlager R, Lim SY, et al. International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson’s disease. Mov Disord. 2018;33(8):1248–1266.
   PubMed Web of Science ®Google Scholar
• Melamed E, Zoldan J, Galili-Mosberg R, et al. Current management of motor fluctuations in patients with advanced Parkinson’s disease treated chronically with levodopa. J Neural Transm Suppl. 1999;56:173–183.
   PubMedGoogle Scholar
• Zangaglia R, Stocchi F, Sciarretta M, et al. Clinical experiences with levodopa methylester (melevodopa) in patients with parkinson disease experiencing motor fluctuations. Clin Neuropharmacol. 2009;33(2):61–66.
   Web of Science ®Google Scholar
• Fasano A, Bove F, Gabrielli M, et al. Melevodopa versus standard levodopa in patients with parkinson disease and small intestinal bacterial overgrowth. Clin Neuropharmacol. 2014;37(4):91–95.
   PubMed Web of Science ®Google Scholar
• Pahwa R, Koller WC, Trosch RM, et al. APO303 Study Investigators. Subcutaneous apomorphine in patients with advanced Parkinson’s disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose. J Neurol Sci. 2007;258(1–2):137–143.
   PubMed Web of Science ®Google Scholar
• Pfeiffer RF, Gutmann L, Hull KL, et al. APO302 Study Investigators. Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson’s disease. Parkinsonism Relat Disord. 2007;13(2):93–100.
   PubMed Web of Science ®Google Scholar
• Dewey RB, Hutton JT, LeWitt PA, et al. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol. 2001;58(9):1385–1392.
   PubMed Web of Science ®Google Scholar
• Ostergaard L, Werdelin L, Odin P, et al. Pen injected apomorphine against off phenomena in late Parkinson’s disease: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry. 1995;58(6):681–687.
   PubMed Web of Science ®Google Scholar
• van Laar T, Jansen EN, Essink AW, et al. A double-blind study of the efficacy of apomorphine and its assessment in ’off’-periods in Parkinson’s disease. Clin Neurol Neurosurg. 1993;95(3):231–235.
   PubMed Web of Science ®Google Scholar
• LeWitt PA. Subcutaneously administered apomorphine: pharmacokinetics and metabolism. Neurology. 2004;62(6 Suppl 4):S8–11.
   PubMed Web of Science ®Google Scholar
• Deleu D, Hanssens Y, Northway MG. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson’s disease. Drugs Aging. 2004;21(11):687–709.
   PubMed Web of Science ®Google Scholar
• Schwab RS, L V A, Lettvin JY. Apomorphine in Parkinson’s disease. Trans Am Neurol Assoc. 1951;56:251–253.
   PubMedGoogle Scholar
• Trenkwalder C, Chaudhuri KR, García Ruiz PJ, et al. Expert consensus group report on the use of apomorphine in the treatment of Parkinson’s disease – clinical practice recommendations. Parkinsonism Relat Disord. 2015;21(9):1023–1030.
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Hauser RA, Grosset DG, et al. A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson’s disease. Mov Disord. 2016;31(9):1356–1365.
   PubMed Web of Science ®Google Scholar
• Titova N, Chaudhuri KR. Apomorphine therapy in Parkinson’s and future directions. Park Relat Disord. 2016;33:S56–S60.
   PubMedGoogle Scholar
• Hauser RA, Olanow CW, Dzyngel B, et al. Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson’s disease. Mov Disord. 2016;31(9):1366–1372.
   PubMed Web of Science ®Google Scholar
• Grosset KA, Malek N, Morgan F, et al. Inhaled apomorphine in patients with “on-off” fluctuations: A randomized, double-blind, placebo-controlled, clinic and home based, parallel-group study. J Parkinsons Dis. 2013;3(1):31–33.
   PubMedGoogle Scholar
• Gänger S, Schindowski K. Tailoring formulations for intranasal nose-to-brain delivery: a review on architecture, physico-chemical characteristics and mucociliary clearance of the nasal olfactory Mucosa. Pharmaceutics. 2018;10(3):116.
   PubMed Web of Science ®Google Scholar
• Frijlink HW, De Boer AH. Dry powder inhalers for pulmonary drug delivery. Expert Opin Drug Deliv. 2004;1(1):67–86.
   PubMedGoogle Scholar
• Luinstra M, Rutgers AWF, Dijkstra H, et al. Can patients with Parkinson’s disease use dry powder inhalers during off periods?. PLoS One. 2015;10(7):e0132714.
   PubMed Web of Science ®Google Scholar
• Sakagami M. In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Adv Drug Deliv Rev. 2006;58(9–10):1030–1060.
   PubMed Web of Science ®Google Scholar
• Telko MJ, Hickey AJ. Dry powder inhaler formulation. Respir Care. 2005;50(9):1209–1227.
   PubMedGoogle Scholar
• Pappert EJ, Buhrfiend C, Lipton JW, et al. Levodopa stability in solution: time course, environmental effects, and practical recommendations for clinical use. Mov Disord. 1996;11(1):24–26.
   PubMed Web of Science ®Google Scholar
• Hoppentocht M, Hagedoorn P, Frijlink HW, et al. Technological and practical challenges of dry powder inhalers and formulations. Adv Drug Deliv Rev. 2014;75:18–31.
   PubMed Web of Science ®Google Scholar
• Demoly P, Hagedoorn P, de Boer AH, et al. The clinical relevance of dry powder inhaler performance for drug delivery. Respir Med. 2014;108(8):1195–1203.
   PubMed Web of Science ®Google Scholar
• Guedes LU, Rodrigues JM, Fernandes AA, et al. Respiratory changes in Parkinson’s disease may be unrelated to dopaminergic dysfunction. Arq Neuropsiquiatr. 2012;70(11):847–851.
   PubMed Web of Science ®Google Scholar
• Khajeh-Hosseini-Dalasm N, Longest PW. Deposition of particles in the alveolar airways: inhalation and breath-hold with pharmaceutical aerosols. J Aerosol Sci. 2015;79:15–30.
   PubMed Web of Science ®Google Scholar
• DeLong M, Wright J, Dawson M, et al. Dose delivery characteristics of the AIR ® pulmonary delivery system over a range of inspiratory flow rates. J Aerosol Med. 2005;18(4):452–459.
   PubMedGoogle Scholar
• LeWitt PA, Pahwa R, Sedkov A, et al. Tolerability of Inhaled Levodopa (CVT-301) Administered to Patients with Parkinson’s Disease. J Aerosol Med Pulm Drug Deliv. 2018;31(3):155–161.
   PubMed Web of Science ®Google Scholar
• Lipp MM, Batycky R, Moore J, et al. Preclinical and clinical assessment of inhaled levodopa for OFF episodes in Parkinson’s disease. Sci Transl Med. 2016;8(360):360ra136.
   PubMed Web of Science ®Google Scholar
• Lewitt PA. Levodopa therapy for Parkinson’s disease: pharmacokinetics and pharmacodynamics. Mov Disord. 2015;30(1):64–72.
   PubMed Web of Science ®Google Scholar
• Bartus RT, Emerich D, Snodgrass-belt P, et al. A pulmonary formulation of l -dopa enhances its effectiveness in a rat model of Parkinson’s disease. J Pharmacol Exp Ther. 2004;310(2):828–835.
   PubMed Web of Science ®Google Scholar
• Freed M, Batycky R, Merica E. Safety, tolerability and levodopa pharmacokinetics following inhaled administration of CVT-301, a levodopa dry powder aerosol, in healthy, adult subjects. Mov Disord. 2013;28:S1542013.
   Web of Science ®Google Scholar
• Schrag A, Sampaio C, Counsell N, et al. Minimal clinically important change on the unified Parkinson’s disease rating scale. Mov Disord. 2006;21(8):1200–1207.
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Hauser RA, Pahwa R, et al. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol. 2019;18(2):145–154.
   PubMed Web of Science ®Google Scholar
• Hauser RA, Isaacson SH, Ellenbogen A, et al. Orally inhaled levodopa (CVT-301) for early morning OFF periods in Parkinson’s disease. Parkinsonism Relat Disord. 2019;64:175-180.
   PubMed Web of Science ®Google Scholar
• Hsu A, Yao H-M, Gupta S, et al. Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet®), sustained-release carbidopa-levodopa (Sinemet® CR), and carbidopa-levodopa-entacapone (Stalevo®). J Clin Pharmacol. 2015;55(9):995–1003.
   PubMed Web of Science ®Google Scholar
• Pezzella FR, Colosimo C, Vanacore N, et al. Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson’s disease. Mov Disord. 2005;20(1):77–81.
   PubMed Web of Science ®Google Scholar
• Giovannoni G, O’Sullivan JD, Turner K, et al. Hedonistic homeostatic dysregulation in patients with Parkinson’s disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry. 2000;68(4):423–428.
   PubMed Web of Science ®Google Scholar
• Allain F, Minogianis EA, Roberts DCS, et al. How fast and how often: the pharmacokinetics of drug use are decisive in addiction. Neurosci Biobehav Rev. 2015;56:166–179.
   PubMed Web of Science ®Google Scholar